Identification and verification of methylation marker sequences
AssigneeSiemens Healthcare Diagnostics Inc.
InventorsChris Beard, Chris Burgess, Allison Gannon, Jeanne Harvey, John F. Lechner, Zheng Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for identifying among the genes that are down-regulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer.
Claims2
-27. (canceled)
A method of screening a biological sample for biomarkers for colon cancer, said method comprising:
- (a) determining the expression level of all or substantially all of nucleic acid sequences of the biological sample which comprise at least one methylated CpG site in a promoter-first exon region;
- (b) determining the expression level of the all or substantially all of nucleic acid sequences that have been demethylated;
- (c) comparing the expression level from step (a) with the expression level from step (b);
- (d) identifying those nucleic acid sequences exhibiting a significant increase in the expression level after demethylation as compared to the expression level of the same nucleic acid sequences in the methylated state.
Dependencies are inferred from the claim text.